Volume | 150,773 |
|
|||||
News | - | ||||||
Day High | 0.7999 | Low High |
|||||
Day Low | 0.7514 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
HOOKIPA Pharma Inc | HOOK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.77 | 0.7514 | 0.7999 | 0.7625 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
479 | 150,773 | $ 0.7744594 | $ 116,768 | - | 0.41 - 2.01 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:57:26 | 60 | $ 0.7611 | USD |
HOOKIPA Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
63.8M | 83.95M | - | 20.13M | -81.58M | -0.97 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
HOOKIPA Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HOOK Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.825 | 0.90 | 0.712 | 0.7813649 | 558,087 | -0.0643 | -7.79% |
1 Month | 0.7095 | 0.90 | 0.6996 | 0.7757557 | 548,829 | 0.0512 | 7.22% |
3 Months | 0.7182 | 0.90 | 0.5789 | 0.723349 | 549,408 | 0.0425 | 5.92% |
6 Months | 0.5397 | 1.13 | 0.41 | 0.7784981 | 1,513,160 | 0.221 | 40.95% |
1 Year | 0.77 | 2.01 | 0.41 | 0.9071177 | 1,211,026 | -0.0093 | -1.21% |
3 Years | 12.52 | 20.00 | 0.41 | 2.01 | 1,200,617 | -11.76 | -93.92% |
5 Years | 14.01 | 20.00 | 0.41 | 2.44 | 754,277 | -13.25 | -94.57% |
HOOKIPA Pharma Description
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies. |